SCHEMBL813415

SCHEMBL813415

CCC1=Cc2cc(-c3ccccc3)ccc2C1[Zr](Cl)(Cl)(C1C(CC)=Cc2cc(-c3ccccc3)ccc21)[SiH](C)C

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.34
KDM1A O60341 2/20 0.30
KDM1B Q8NB78 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL812358 0.84 KDM1A (0.31) KDM1AKDM1B
SCHEMBL272945 0.82
SCHEMBL5952773 0.78
SCHEMBL5951101 0.77
SCHEMBL138390 0.76
SCHEMBL5610175 0.74
SCHEMBL5609610 0.74 KDM4E (0.31)
Hydrochloric Acid SCHEMBL813414 0.74 BCL2 (0.34) BCL2
SCHEMBL5597485 0.73
SCHEMBL5278351 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896525-B2 Homogeneous polymerization process using evaporative cooling EXXONMOBIL CHEMICAL PATENTS INC. (US) 2018-02-20 US claimed
WO-2016175962-A1 HOMOGENEOUS POLYMERIZATION PROCESS USING EVAPORATIVE COOLING EXXONMOBIL CHEMICAL PATENTS INC. (US) 2016-11-03 WO claimed
US-20160319054-A1 Homogeneous Polymerization Process Using Evaporative Cooling EXXONMOBIL CHEMICAL PATENTS INC. 2016-11-03 US claimed
JP-4664080-B2 2011-04-06 JP claimed
US-7741420-B2 Polymer production at supercritical conditions EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-06-22 US claimed
US-7429634-B2 Polymer production at supercritical conditions EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-09-30 US claimed
US-7354979-B2 Polymer production at supercritical conditions EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-04-08 US claimed
US-20070255018-A1 Polymer Production at Supercritical Conditions EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-11-01 US claimed
US-20060211832-A1 Polymer production at supercritical conditions BRANT PATRICK 2006-09-21 US claimed
JP-2006510796-A 2006-03-30 JP claimed
WO-2006019494-A1 POLYMER PRODUCTION AT SUPERCRITICAL CONDITIONS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-02-23 WO claimed
EP-1539841-A1 POLYMER PRODUCTION AT SUPERCRITICAL CONDITIONS ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware (US) 2005-06-15 EP claimed
US-20040127654-A1 Polymer production at supercritical conditions EXXONMOBIL CHEMICAL PATENTS INC. 2004-07-01 US claimed
WO-2004026921-A1 POLYMER PRODUCTION AT SUPERCRITICAL CONDITIONS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-04-01 WO claimed
US-12528892-B2 Alkylation of transition metal coordination catalyst complexes EXXONMOBIL CHEMICAL PATENTS INC. (US) 2026-01-20 US disclosed
US-11708434-B2 Silica quenching agents for use in polymerization process EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-07-25 US disclosed
US-20230141606-A1 Alkylation of Transition Metal Coordination Catalyst Complexes EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-05-11 US disclosed
EP-1539841-A1 POLYMER PRODUCTION AT SUPERCRITICAL CONDITIONS ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware (US) 2005-06-15 EP disclosed
US-20040127654-A1 Polymer production at supercritical conditions EXXONMOBIL CHEMICAL PATENTS INC. 2004-07-01 US disclosed
WO-2004026921-A1 POLYMER PRODUCTION AT SUPERCRITICAL CONDITIONS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528892-B2 Alkylation of transition metal coordination catalyst complexes LEF1, TAF1, FLI1 BCL2 1426/4885KDM1A 2188/4885KDM1B 2785/4885
US-20230141606-A1 Alkylation of Transition Metal Coordination Catalyst Complexes AS3MT, AP1M1, AP3M1 BCL2 4475/4885KDM1A 2465/4885KDM1B 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.